120 related articles for article (PubMed ID: 28239880)
41. Utility of Prediction Scores for Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Treated with Nucleos(t)ide Analogues.
Tawada A; Chiba T; Saito T; Ogasawara S; Suzuki E; Ooka Y; Arai M; Kanda T; Shinozaki M; Goto N; Nagashima K; Yokosuka O
Oncology; 2016; 90(4):199-208. PubMed ID: 26934505
[TBL] [Abstract][Full Text] [Related]
42. Tenofovir disoproxil fumarate significantly decreases serum lipoprotein levels compared with entecavir nucleos(t)ide analogue therapy in chronic hepatitis B carriers.
Shaheen AA; AlMattooq M; Yazdanfar S; Burak KW; Swain MG; Congly SE; Borman MA; Lee SS; Myers RP; Coffin CS
Aliment Pharmacol Ther; 2017 Sep; 46(6):599-604. PubMed ID: 28707319
[TBL] [Abstract][Full Text] [Related]
43. Effects of nucleoside analogue prescription for hepatitis B on the incidence of liver cancer in Hong Kong: a territory-wide ecological study.
Seto WK; Lau EH; Wu JT; Hung IF; Leung WK; Cheung KS; Fung J; Lai CL; Yuen MF
Aliment Pharmacol Ther; 2017 Feb; 45(4):501-509. PubMed ID: 27976416
[TBL] [Abstract][Full Text] [Related]
44. Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency.
Wong DK; Seto WK; Fung J; Ip P; Huang FY; Lai CL; Yuen MF
Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1004-10.e1. PubMed ID: 23376799
[TBL] [Abstract][Full Text] [Related]
45. Nationwide cohort study suggests that nucleos(t)ide analogue therapy decreases dialysis risk in Taiwanese chronic kidney disease patients acquiring hepatitis B virus infection.
Chen YC; Li CY; Tsai SJ; Chen YC
World J Gastroenterol; 2018 Feb; 24(8):917-928. PubMed ID: 29491685
[TBL] [Abstract][Full Text] [Related]
46. Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine.
Papatheodoridis GV; Dimou E; Dimakopoulos K; Manolakopoulos S; Rapti I; Kitis G; Tzourmakliotis D; Manesis E; Hadziyannis SJ
Hepatology; 2005 Jul; 42(1):121-9. PubMed ID: 15962291
[TBL] [Abstract][Full Text] [Related]
47. Meta-analysis: the impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B.
Singal AK; Salameh H; Kuo YF; Fontana RJ
Aliment Pharmacol Ther; 2013 Jul; 38(2):98-106. PubMed ID: 23713520
[TBL] [Abstract][Full Text] [Related]
48. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study.
Papatheodoridis GV; Manolakopoulos S; Touloumi G; Vourli G; Raptopoulou-Gigi M; Vafiadis-Zoumbouli I; Vasiliadis T; Mimidis K; Gogos C; Ketikoglou I; Manesis EK;
Gut; 2011 Aug; 60(8):1109-16. PubMed ID: 21270118
[TBL] [Abstract][Full Text] [Related]
49. Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy.
Li N; Xu JH; Yu M; Wang S; Si CW; Yu YY
World J Gastroenterol; 2015 Nov; 21(43):12421-9. PubMed ID: 26604649
[TBL] [Abstract][Full Text] [Related]
50. Chronic hepatitis B prognostic markers other than pre-treatment viral load predicted composite treatment outcome.
Aung MN; Leowattana W; Win KN; Tangpukdee N; Muangnoicharoen S
J Infect Dev Ctries; 2013 Jul; 7(7):541-9. PubMed ID: 23857389
[TBL] [Abstract][Full Text] [Related]
51. Long-term outcome of hepatitis B virus-related Chronic Hepatitis under protracted nucleos(t)ide analogues.
Niro GA; Ippolito AM; Fontana R; Valvano MR; Gioffreda D; Iacobellis A; Merla A; Durazzo M; Lotti G; Di Mauro L; Andriulli A
J Viral Hepat; 2013 Jul; 20(7):502-9. PubMed ID: 23730844
[TBL] [Abstract][Full Text] [Related]
52. [A retrospective follow-up study of prolonged nucleos(t)ide analogue and interferon combination therapy in HBeAg-positive chronic hepatitis B patients].
Yu SL; Guo CY
Zhonghua Gan Zang Bing Za Zhi; 2013 Apr; 21(4):267-70. PubMed ID: 24021787
[TBL] [Abstract][Full Text] [Related]
53. Disease Progression in Chronic Hepatitis B Patients under Long-Term Antiviral Therapy.
Moon JC; Kim SH; Kim IH; Lee CH; Kim SW; Lee SO; Lee ST; Kim DG
Gut Liver; 2015 May; 9(3):395-404. PubMed ID: 25473072
[TBL] [Abstract][Full Text] [Related]
54. Increasing antiviral treatment uptake improves survival in patients with HBV-related HCC.
Hui VW; Chan SL; Wong VW; Liang LY; Yip TC; Lai JC; Yuen BW; Luk HW; Tse YK; Lee HW; Chan HL; Wong GL
JHEP Rep; 2020 Dec; 2(6):100152. PubMed ID: 33024950
[TBL] [Abstract][Full Text] [Related]
55. Long-term efficacy of tenofovir disoproxil fumarate therapy after multiple nucleos(t)ide analogue failure in chronic hepatitis B patients.
Kim HJ; Cho JY; Kim YJ; Gwak GY; Paik YH; Choi MS; Koh KC; Paik SW; Yoo BC; Lee JH
Korean J Intern Med; 2015 Jan; 30(1):32-41. PubMed ID: 25589833
[TBL] [Abstract][Full Text] [Related]
56. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability.
Kim GA; Lim YS; An J; Lee D; Shim JH; Kim KM; Lee HC; Chung YH; Lee YS; Suh DJ
Gut; 2014 Aug; 63(8):1325-32. PubMed ID: 24162593
[TBL] [Abstract][Full Text] [Related]
57. Amino acid similarities and divergences in the small surface proteins of genotype C hepatitis B viruses between nucleos(t)ide analogue-naïve and lamivudine-treated patients with chronic hepatitis B.
Ding H; Liu B; Zhao C; Yang J; Yan C; Yan L; Zhuang H; Li T
Antiviral Res; 2014 Feb; 102():29-34. PubMed ID: 24316031
[TBL] [Abstract][Full Text] [Related]
58. Ten-year follow-up of hepatitis B relapse after cessation of lamivudine or telbivudine treatment in chronic hepatitis B patients.
Pan HY; Pan HY; Chen L; Yang DH; Huang HJ; Tong YX; Chen CR; Yan J
Clin Microbiol Infect; 2015 Dec; 21(12):1123.e1-9. PubMed ID: 26253290
[TBL] [Abstract][Full Text] [Related]
59. Review article: the potential of interferon and nucleos(t)ide analogue combination therapy in chronic hepatitis B infection.
Viganò M; Invernizzi F; Grossi G; Lampertico P
Aliment Pharmacol Ther; 2016 Oct; 44(7):653-61. PubMed ID: 27528410
[TBL] [Abstract][Full Text] [Related]
60. [Is it possible to stop treatment with nucleos(t)ide analogs in patients with e-antigen negative chronic hepatitis B? Experience and new expectations].
Martín Mateos RM; Moreira Vicente VF; Tavío Hernández E; Cuño Roldán JL; Téllez Villajos L; Aicart Ramos M; Arribas Anta J; Zaera de la Fuente C; Albillos Martínez A
Gastroenterol Hepatol; 2015 May; 38(5):305-12. PubMed ID: 25636371
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]